Scientific deep-dive

Lifestyle Plus the Drug

Across 98,261 veterans with type 2 diabetes, taking a GLP-1 and keeping six to eight healthy habits was associated with 43% fewer cardiovascular events than three or fewer habits and no drug. The two figures people will compare cannot be compared.

By Nora Bissett · Pricing Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed
5 min read·1 citation

The tiresome argument about whether people should “just eat better instead” now has data from 98,261 veterans with type 2 diabetes followed across 632,543 person-years. Doing both was linked to fewer cardiovascular events than doing either. People taking a GLP-1 and keeping six to eight healthy habits had 43% fewer major cardiovascular events than people with three or fewer habits and no drug.[1]

What was measured

Adjusted hazard ratios for major adverse cardiovascular events. Note that the comparison groups differ between rows.
ComparisonHazard ratio
All eight low-risk lifestyle habits vs one or fewer0.40 (95% CI 0.30–0.54)
GLP-1 users vs non-users0.84 (95% CI 0.76–0.92)
GLP-1 plus six to eight habits vs three or fewer habits and no GLP-10.57 (95% CI 0.46–0.71)

The authors’ conclusion is that combining lifestyle change with pharmacotherapy was associated with a greater reduction than either approach alone.[1]

The comparison you cannot make from this table

It is tempting to set 0.40 against 0.84 and conclude lifestyle is roughly four times more powerful than the drug. The table cannot support that comparison, and it is the misreading this study will be used for.

The rows are different contrasts. One compares the extremes of an eight-point gradient; the other compares taking a drug against not taking it.

“Eight habits versus one or fewer” contrasts the healthiest people in the dataset against the least healthy across a wide range of behaviors. “GLP-1 user versus non-user” is a single yes-or-no. Those produce numbers that cannot be ranked against each other, any more than you could compare the effect of “the top versus bottom of a scale” with “on versus off a switch”.

There is a second problem specific to lifestyle findings in observational data. Adhering to eight healthy habits is not randomly distributed. It correlates with income, housing, working hours, disability, and every other advantage that independently predicts cardiovascular outcomes. Adjustment reduces that confounding but does not remove it. Only randomization does, and lifestyle trials that count heart attacks rather than kilograms are rare; one assigned people with heart disease to a Mediterranean or a low-fat diet and followed them for seven years.

What the finding does support

  • The two are not alternatives. This is the useful part. Public debate usually frames them as a choice between one and the other.
  • Taking the drug does not make lifestyle irrelevant. The authors conclude that the drug combined with the habits was associated with a greater reduction in risk than either on its own.
  • The drug is not a substitute for the habits, and the habits are not a reason to refuse the drug. The data support both halves of that.
  • It is consistent with the randomized picture. In a four-arm trial we covered in exercise plus a GLP-1, the drug alone did nothing for physical fitness while exercise did, and the combination did most.
This is an observational study of veterans with type 2 diabetes, so it establishes association rather than causation, and the population is not representative (predominantly older and male). Its direction is consistent with the rest of the evidence, which is why we cite it, but it is not a trial.

Frequently Asked Questions

You cannot tell from this study, and it is the misreading to avoid. The lifestyle figure compares the extremes of a wide gradient, people with eight healthy habits against people with one or fewer, while the drug figure compares taking it against not. Those are different kinds of comparison and cannot be ranked.
That is what the authors conclude, from an association rather than a trial. People taking a GLP-1 and keeping six to eight low-risk lifestyle habits had 43% fewer major cardiovascular events than people with three or fewer habits and no drug, and the authors read that as the combination being associated with a greater reduction than either approach on its own.
No. The authors conclude that the drug combined with healthy habits was associated with a greater reduction in cardiovascular risk than either approach alone, and a separate randomized trial found the drug alone produced no improvement in physical fitness while exercise did.
Less than it looks. Adhering to eight healthy habits correlates with income, housing, working hours and disability, and each of those independently predicts cardiovascular outcomes. Statistical adjustment reduces that problem without removing it.
98,261 people with type 2 diabetes and no previous heart attack, stroke or advanced kidney disease, in a Veterans Affairs population, followed across 632,543 person-years, during which 10,443 developed a major cardiovascular event. It is observational, and the population skews older and male, so it does not show whether the same holds for people without diabetes.

References

  1. 1.Nguyen XT, Li Y, Czernichow S, et al. Combined associations of GLP-1 receptor agonists and a healthy lifestyle with cardiovascular outcomes among individuals with type 2 diabetes The Lancet Diabetes & Endocrinology. 2026. PMID: 41763234.

How Far You Can Walk

Peripheral artery disease stops people walking, and almost nothing improves it. A trial of 792 people measured actual walking distance, and the spread matters as much as the median.

6 min read

Semaglutide and Peripheral Artery Disease: The Label, the Options and Coverage

STRIDE showed semaglutide 1 mg improved walking distance in type 2 diabetes with PAD, and Novo Nordisk filed for a US label change in 2025. Ozempic's label still lists no PAD use, but PAD already counts as cardiovascular disease on the Ozempic and Wegovy labels.

7 min read

Muscle Loss: Drug Versus Dieting

Across 20 trials in 15,782 people, lean mass made up the same fraction of weight lost on incretin drugs as on dieting (p=0.42). Adding resistance training cut it from about a quarter to 17.5%.

6 min read

Metformin vs GLP-1 for Longevity: The TAME Trial Has Not Started

No trial shows metformin extends life in people without diabetes. TAME, the metformin aging trial, has no registry record and was still unfunded at last report. Semaglutide has randomized outcome data, but only in people already at high risk.

9 min read

Exercise Plus a GLP-1: What Each One Actually Changes

In a four-arm randomized trial, the drug alone produced no improvement in physical fitness. Exercise did, with or without the drug, and the strength result needs reading carefully.

6 min read

Diastasis Recti and Weight Loss: What GLP-1s, Exercise and Surgery Change

Diastasis recti is a widened seam between the ab muscles, common after pregnancy and not a hernia. What the studies show on weight as a risk factor, why a belly can still bulge after GLP-1 weight loss, how little exercise closes the gap, and surgical repair.

11 min read

Where to get GLP-1 online, safely: sellers our editors have checked

These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.

No insurance needed · vetted by our editors

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

6.3

WellMedRx

Comparing compounded and brand GLP-1 plans with a published state list

8.8

altRX

Compounded semaglutide from $89/month at the same price at every dose

9.0

CoreAge Rx

Flat-priced compounded semaglutide at $79 a month, any dose

About this analysis

GLP Watchdog publishes independently. Each seller in our dataset is checked against that seller's own website, and the dataset is updated continuously. Read our full methodology →